Home / LPCN : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does LPCN make money? Does LPCN have pricing power? What's the Earnings Whisper? Will LPCN profit more as the business scales? What is LPCN's management track record? Is LPCN's current price justified?

Lipocine Inc.

$2.27 -$5.73 (-71.62%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$2.25

Day Range

$2.25$2.29

Year Range

$1.81$12.37

Market Cap

18.71M

AVG Volume

64.88K

Trailing/Forward PE

-1.21/-

PEG ratio

-0.19

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Revenue (USD) · TTM

LPCN Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	1.57M
26 Q1	2M
25 Q4	1.98M
25 Q3	4.32M
25 Q2	4.21M
25 Q1	3.67M
24 Q4	11.2M
24 Q3	7.92M
24 Q2	4.8M
24 Q1	4.71M

Net Income (USD) · TTM

LPCN Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-11.85M
26 Q1	-11.43M
25 Q4	-9.63M
25 Q3	-5.48M
25 Q2	-4.51M
25 Q1	-5.37M
24 Q4	8.35K
24 Q3	-4.06M
24 Q2	-8.49M
24 Q1	-8.97M

Operating Income (USD) · TTM

LPCN Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-12.57M
26 Q1	-12.13M
25 Q4	-10.37M
25 Q3	-6.31M
25 Q2	-5.58M
25 Q1	-6.47M
24 Q4	-1.16M
24 Q3	-5.29M
24 Q2	-9.71M
24 Q1	-10.37M

EBITDA (USD) · TTM

LPCN EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-11.79M
26 Q1	-11.37M
25 Q4	-9.57M
25 Q3	-5.41M
25 Q2	-4.45M
25 Q1	-5.32M
24 Q4	50.14K
24 Q3	-4.02M
24 Q2	-8.45M
24 Q1	-8.94M

Cash Flows (USD) · TTM

LPCN Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-11.19M
26 Q1	-10.05M
25 Q4	-9.76M
25 Q3	-5.15M
25 Q2	-5.08M
25 Q1	-5.69M
24 Q4	-1.31M
24 Q3	-5.03M
24 Q2	-4.73M
24 Q1	-5.54M

EPS (USD) · TTM

LPCN EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-1.87
26 Q1	-1.96
25 Q4	-1.77
25 Q3	-1.03
25 Q2	-0.85
25 Q1	-1.01
24 Q4	0
24 Q3	-0.75
24 Q2	-1.6
24 Q1	-1.71

Expenses (USD) · TTM

LPCN Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	14.14M
26 Q1	14.12M
25 Q4	12.35M
25 Q3	10.63M
25 Q2	9.86M
25 Q1	8.36M
24 Q4	10.57M
24 Q3	9.76M
24 Q2	10.97M
24 Q1	10.9M

Shares Outstanding (USD) · TTM

LPCN Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-229.83K
26 Q1	-236.89K
25 Q4	-242.5K
25 Q3	-288.55K
25 Q2	-343.19K
25 Q1	-380.25K
24 Q4	-408.55K
24 Q3	-463.18K
24 Q2	-513.37K
24 Q1	-575.97K

Employee Count

LPCN Employee Count by quarter
Period	Employee Count
2025	14
2024	16
2023	17
2022	17
2021	13
2020	11
2019	12
2018	10
2017	14
2016	14

PE Ratio

LPCN PE Ratio by quarter
Period	PE Ratio
May 25	2135.07
Apr 25	2039.18
Apr 25	1917.73
Apr 25	1962.48
Apr 25	1924.12
Mar 25	2096.72
Mar 25	2262.92
Mar 25	2141.46
Mar 23	8.42
Feb 23	8.25
Feb 23	9.6
Feb 23	10.15
Feb 23	10.56
Jan 23	10.27
Jan 23	10.37
Jan 23	10.67
Jan 23	9.21
Dec 22	7.64
Dec 22	7.79
Dec 22	8.16
Dec 22	7.78
Dec 22	8.64
Nov 22	9.16
Nov 22	9.21
Nov 22	7.32
Nov 22	8.47
Oct 22	8.84
Oct 22	9.44
Oct 22	9.63
Oct 22	9.74
Sep 22	9.63
Sep 22	10.63
Sep 22	12.13
Sep 22	11.03
Sep 22	12.2
Aug 22	12.52
Aug 22	13.05
Aug 22	15.1

Free Cash Flow Yield

LPCN Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-60%
Sep 26	-55.59%
Aug 26	-62.76%
Aug 26	-65.16%
Aug 26	-64.55%
Aug 26	-63.94%
Jul 26	-69.76%
Jul 26	-71.1%
Jul 26	-66.31%
Jul 26	-61.36%
Jul 26	-61.88%
Jun 26	-60.11%
Jun 26	-63.47%
Jun 26	-65.43%
Jun 26	-72.14%
May 26	-65.73%
May 26	-65.43%
May 26	-65.43%
May 26	-62.4%
May 26	-76.88%
Apr 26	-74.02%
Apr 26	-73.72%
Apr 26	-81.42%
Apr 26	-87.38%
Mar 26	-25.05%
Mar 26	-25.05%
Mar 26	-24.41%
Mar 26	-11.7%
Feb 26	-9.55%
Feb 26	-9.71%
Feb 26	-10.98%
Feb 26	-11.2%
Jan 26	-10.57%
Jan 26	-8.72%
Jan 26	-8.55%
Jan 26	-11.88%
Jan 26	-11.89%
Dec 25	-18.19%
Dec 25	-22.38%
Dec 25	-30.01%
Dec 25	-30.2%
Nov 25	-27.65%
Nov 25	-30.1%
Nov 25	-33.14%
Nov 25	-37.45%
Oct 25	-35.66%
Oct 25	-32.71%
Oct 25	-31.41%
Oct 25	-30.6%
Oct 25	-28.31%
Sep 25	-34.75%
Sep 25	-32.94%
Sep 25	-31.83%
Sep 25	-32.82%
Aug 25	-32.6%
Aug 25	-30.5%
Aug 25	-31.3%
Aug 25	-32.37%
Aug 25	-33.76%
Jul 25	-30.92%
Jul 25	-34.09%
Jul 25	-32.52%
Jul 25	-34.31%
Jun 25	-32.32%
Jun 25	-32.23%
Jun 25	-34.09%
Jun 25	-33.55%
May 25	-31.46%
May 25	-29.71%
May 25	-26.65%
May 25	-32.42%
May 25	-7.35%
Apr 25	-7.7%
Apr 25	-8.19%
Apr 25	-8%
Apr 25	-8.16%
Mar 25	-7.49%
Mar 25	-6.94%
Mar 25	-7.33%
Mar 25	-27.37%
Feb 25	-30.67%
Feb 25	-27.85%
Feb 25	-25.93%
Feb 25	-26.9%
Jan 25	-21.79%
Jan 25	-20.07%
Jan 25	-21.54%
Jan 25	-19.25%
Jan 25	-18.61%
Dec 24	-19.78%
Dec 24	-19.33%
Dec 24	-18.75%
Dec 24	-18.46%
Nov 24	-20.74%
Nov 24	-18.28%
Nov 24	-19.25%
Nov 24	-19.78%
Nov 24	-14.55%
Oct 24	-15.33%
Oct 24	-16.92%

Price to Sales

LPCN Price to Sales by quarter
Period	Price to Sales
Sep 26	11.88
Sep 26	12.83
Aug 26	11.36
Aug 26	10.94
Aug 26	11.05
Aug 26	11.15
Jul 26	7.19
Jul 26	7.06
Jul 26	7.57
Jul 26	8.18
Jul 26	8.11
Jun 26	8.35
Jun 26	7.91
Jun 26	7.67
Jun 26	6.96
May 26	7.64
May 26	7.67
May 26	7.67
May 26	8.04
May 26	6.42
Apr 26	6.67
Apr 26	6.7
Apr 26	6.06
Apr 26	5.65
Mar 26	19.71
Mar 26	19.71
Mar 26	20.23
Mar 26	10.18
Feb 26	12.47
Feb 26	12.27
Feb 26	10.84
Feb 26	10.63
Jan 26	11.27
Jan 26	13.66
Jan 26	13.94
Jan 26	10.03
Jan 26	10.02
Dec 25	6.55
Dec 25	5.32
Dec 25	3.97
Dec 25	3.94
Nov 25	4.31
Nov 25	3.96
Nov 25	3.59
Nov 25	3.18
Oct 25	3.38
Oct 25	3.69
Oct 25	3.84
Oct 25	3.94
Oct 25	4.26
Sep 25	3.47
Sep 25	3.66
Sep 25	3.79
Sep 25	3.68
Aug 25	3.7
Aug 25	3.96
Aug 25	3.85
Aug 25	3.73
Aug 25	4.58
Jul 25	5.01
Jul 25	4.54
Jul 25	4.76
Jul 25	4.51
Jun 25	4.79
Jun 25	4.8
Jun 25	4.54
Jun 25	4.61
May 25	4.92
May 25	5.21
May 25	5.81
May 25	4.77
May 25	1.59
Apr 25	1.52
Apr 25	1.43
Apr 25	1.46
Apr 25	1.44
Mar 25	1.56
Mar 25	1.69
Mar 25	1.6
Mar 25	2.32
Feb 25	2.07
Feb 25	2.28
Feb 25	2.45
Feb 25	2.36
Jan 25	2.92
Jan 25	3.17
Jan 25	2.95
Jan 25	3.3
Jan 25	3.42
Dec 24	3.21
Dec 24	3.29
Dec 24	3.39
Dec 24	3.44
Nov 24	3.06
Nov 24	3.48
Nov 24	3.3
Nov 24	3.21
Nov 24	6.77
Oct 24	6.42
Oct 24	5.82

EV/EBITDA

LPCN EV/EBITDA by quarter
Period	EV/EBITDA
May 25	-75.81
Apr 25	-91.79
Apr 25	-112.02
Apr 25	-104.56
Apr 25	-110.95
Mar 25	-82.2
Mar 25	-54.52
Mar 25	-74.75
Mar 23	0.06
Feb 23	-0.11
Feb 23	1.21
Feb 23	1.76
Feb 23	2.16
Jan 23	1.88
Jan 23	1.97
Jan 23	2.27
Jan 23	0.84
Dec 22	-0.71
Dec 22	-0.56
Dec 22	-0.2
Dec 22	-0.58
Dec 22	0.27
Nov 22	0.78
Nov 22	0.84
Nov 22	-1.03
Nov 22	-2.38
Oct 22	-2.02
Oct 22	-1.44
Oct 22	-1.26
Oct 22	-1.15
Sep 22	-1.26
Sep 22	-0.28
Sep 22	1.17
Sep 22	0.1
Sep 22	1.23
Aug 22	1.55
Aug 22	2.06
Aug 22	4.05

Price to Book

LPCN Price to Book by quarter
Period	Price to Book
Sep 26	0.86
Sep 26	0.92
Aug 26	0.82
Aug 26	0.79
Aug 26	0.8
Aug 26	0.8
Jul 26	0.63
Jul 26	0.62
Jul 26	0.66
Jul 26	0.72
Jul 26	0.71
Jun 26	0.73
Jun 26	0.69
Jun 26	0.67
Jun 26	0.61
May 26	0.67
May 26	0.67
May 26	0.67
May 26	0.71
May 26	0.88
Apr 26	0.91
Apr 26	0.91
Apr 26	0.83
Apr 26	0.77
Mar 26	2.69
Mar 26	2.69
Mar 26	2.76
Mar 26	3.11
Feb 26	3.81
Feb 26	3.75
Feb 26	3.31
Feb 26	3.25
Jan 26	3.44
Jan 26	4.18
Jan 26	4.26
Jan 26	3.07
Jan 26	3.06
Dec 25	2
Dec 25	1.63
Dec 25	1.21
Dec 25	1.21
Nov 25	1.32
Nov 25	1.21
Nov 25	1.1
Nov 25	0.97
Oct 25	0.83
Oct 25	0.91
Oct 25	0.94
Oct 25	0.97
Oct 25	1.05
Sep 25	0.85
Sep 25	0.9
Sep 25	0.93
Sep 25	0.9
Aug 25	0.91
Aug 25	0.97
Aug 25	0.95
Aug 25	0.92
Aug 25	0.88
Jul 25	0.96
Jul 25	0.87
Jul 25	0.91
Jul 25	0.86
Jun 25	0.92
Jun 25	0.92
Jun 25	0.87
Jun 25	0.88
May 25	0.94
May 25	1
May 25	1.11
May 25	0.91
May 25	0.85
Apr 25	0.81
Apr 25	0.76
Apr 25	0.78
Apr 25	0.77
Mar 25	0.83
Mar 25	0.9
Mar 25	0.85
Mar 25	0.96
Feb 25	0.86
Feb 25	0.95
Feb 25	1.02
Feb 25	0.98
Jan 25	1.21
Jan 25	1.31
Jan 25	1.22
Jan 25	1.37
Jan 25	1.42
Dec 24	1.33
Dec 24	1.36
Dec 24	1.4
Dec 24	1.43
Nov 24	1.27
Nov 24	1.44
Nov 24	1.37
Nov 24	1.33
Nov 24	1.53
Oct 24	1.45
Oct 24	1.32

No video analysis for this stock yet. Request one from our team.

News: LPCN

prnewswire.com · 10 Sep 2026

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C.

prnewswire.com · 4 Aug 2026

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April 2, 2026, Lipocine reported topline results from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (oral brexanolone) for the treatment of PPD.

prnewswire.com · 3 Aug 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.